Based on the Ardelyx Inc stock forecast from 6 analysts, the average analyst target price for Ardelyx Inc is USD 10.32 over the next 12 months. Ardelyx Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Ardelyx Inc is Neutral, which is based on 5 positive signals and 5 negative signals. At the last closing, Ardelyx Inc’s stock price was USD 4.81. Ardelyx Inc’s stock price has changed by +2.56% over the past week, -10.09% over the past month and -26.23% over the last year.
No recent analyst target price found for Ardelyx Inc
No recent average analyst rating found for Ardelyx Inc
Company Overview Ardelyx Inc
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. Read Less
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with...Read More
Frequently Asked Questions About Ardelyx Inc (ARDX) Stock
Based on ratings from 6 analysts Ardelyx Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 9 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on ARDX's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for ARDX is USD 10.32 over the next 12 months. The maximum analyst target price is USD 13.5 while the minimum anlayst target price is USD 5.5.
Unfortunately we do not have enough data on ARDX's stock to indicate if its overvalued.
The last closing price of ARDX's stock was USD 4.81.
The most recent market capitalization for ARDX is USD 1.35B.
Based on targets from 6 analysts, the average taret price for ARDX is projected at USD 10.32 over the next 12 months.
This means that ARDX's stock price may go up by +114.52% over the next 12 months.
We can't find any ETFs which contains Ardelyx Inc's stock.
As per our most recent records Ardelyx Inc has 267 Employees.
Ardelyx Inc's registered address is 400 Fifth Avenue, Waltham, MA, United States, 02451.
You can get more information about it from Ardelyx Inc's website at https://www.ardelyx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Ardelyx Inc (ARDX) Stock
Based on ratings from 6 analysts Ardelyx Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 9 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on ARDX's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for ARDX is USD 10.32 over the next 12 months. The maximum analyst target price is USD 13.5 while the minimum anlayst target price is USD 5.5.
Unfortunately we do not have enough data on ARDX's stock to indicate if its overvalued.
The last closing price of ARDX's stock was USD 4.81.
The most recent market capitalization for ARDX is USD 1.35B.
Based on targets from 6 analysts, the average taret price for ARDX is projected at USD 10.32 over the next 12 months.
This means that ARDX's stock price may go up by +114.52% over the next 12 months.
We can't find any ETFs which contains Ardelyx Inc's stock.
As per our most recent records Ardelyx Inc has 267 Employees.
Ardelyx Inc's registered address is 400 Fifth Avenue, Waltham, MA, United States, 02451.
You can get more information about it from Ardelyx Inc's website at https://www.ardelyx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ARDX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
